CA2868534A1 - Compositions et traitements bases sur la modulation de la cadherine - Google Patents

Compositions et traitements bases sur la modulation de la cadherine Download PDF

Info

Publication number
CA2868534A1
CA2868534A1 CA2868534A CA2868534A CA2868534A1 CA 2868534 A1 CA2868534 A1 CA 2868534A1 CA 2868534 A CA2868534 A CA 2868534A CA 2868534 A CA2868534 A CA 2868534A CA 2868534 A1 CA2868534 A1 CA 2868534A1
Authority
CA
Canada
Prior art keywords
cadherin
wound
protein
optionally
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2868534A
Other languages
English (en)
Inventor
Bradford J. Duft
David L. Becker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inflammx Therapeutics Inc
Original Assignee
CoDa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/844,553 external-priority patent/US20140274872A1/en
Application filed by CoDa Therapeutics Inc filed Critical CoDa Therapeutics Inc
Publication of CA2868534A1 publication Critical patent/CA2868534A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
CA2868534A 2012-03-27 2013-03-26 Compositions et traitements bases sur la modulation de la cadherine Abandoned CA2868534A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261616393P 2012-03-27 2012-03-27
US61/616,393 2012-03-27
US13/844,553 US20140274872A1 (en) 2013-03-15 2013-03-15 Compositions and treatments based on cadherin modulation
US13/844,553 2013-03-15
PCT/US2013/033948 WO2013148736A1 (fr) 2012-03-27 2013-03-26 Compositions et traitements basés sur la modulation de la cadhérine

Publications (1)

Publication Number Publication Date
CA2868534A1 true CA2868534A1 (fr) 2013-10-03

Family

ID=48184448

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2868534A Abandoned CA2868534A1 (fr) 2012-03-27 2013-03-26 Compositions et traitements bases sur la modulation de la cadherine

Country Status (5)

Country Link
EP (1) EP2831233A1 (fr)
JP (1) JP2015513905A (fr)
CN (1) CN104736709A (fr)
CA (1) CA2868534A1 (fr)
WO (1) WO2013148736A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
CN105250334A (zh) * 2015-10-29 2016-01-20 广州赛莱拉干细胞科技股份有限公司 一种改善皮肤的制剂及其制备方法
US11820981B2 (en) 2016-09-14 2023-11-21 Agency For Science, Technology And Research Modulation of TJP1 expression to regulate regeneration of heart cells
WO2020045652A1 (fr) * 2018-08-31 2020-03-05 株式会社 資生堂 Procédé de détermination de l'état de la peau ou de l'activité cellulaire de cellules cutanées, et procédé de criblage pour activateurs de cellules cutanées
EP4402264A4 (fr) * 2021-09-16 2025-10-15 Agency Science Tech & Res Modulation de l'expression de tjp1 pour traiter des maladies hépatiques
CN117919451B (zh) * 2024-03-21 2024-07-05 中国人民解放军军事科学院军事医学研究院 与桥粒芯糖蛋白2相关的生物材料的应用及抑制骨再生病理性亢进的药物

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US623499A (en) 1899-04-18 Leasuring-can
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4940456A (en) 1987-02-10 1990-07-10 Dan Sibalis Electrolytic transdermal delivery of proteins
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5749847A (en) 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5147296A (en) 1988-10-03 1992-09-15 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5169382A (en) 1988-10-03 1992-12-08 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5064655A (en) 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5484604A (en) 1990-07-21 1996-01-16 Chatfield Pharmaceuticals Limited Cross-linked alginate transdermal medicine delivery devices
US5362308A (en) 1990-09-25 1994-11-08 Rutgers, The State University Of New Jersey Disposable dosage unit for iontophoresis-facilitated transdermal delivery, related devices and processes
US5320850A (en) 1990-10-29 1994-06-14 Alza Corporation Transdermal delivery of the gestogen ST-1435 and devices therefor
US5279544A (en) 1990-12-13 1994-01-18 Sil Medics Ltd. Transdermal or interdermal drug delivery devices
CA2097163C (fr) 1992-06-01 2002-07-30 Marianna Foldvari Timbre topique pour administration d'un medicament liposomal
KR0134151B1 (ko) 1994-05-23 1998-04-14 이형도 인슐린 패치
JPH0912448A (ja) 1995-04-28 1997-01-14 Read Chem Kk 薬物放出制御型経皮吸収製剤
ATE255450T1 (de) 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US6041253A (en) 1995-12-18 2000-03-21 Massachusetts Institute Of Technology Effect of electric field and ultrasound for transdermal drug delivery
JP2002515786A (ja) 1996-06-28 2002-05-28 ソントラ メディカル,エル.ピー. 経皮輸送の超音波増強
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
FR2755842B1 (fr) 1996-11-19 1999-04-23 Lhd Lab Hygiene Dietetique Procede de mesure de la resistance electrique cutanee d'un patient soumis a une administration transdermique de medicament
GB9708066D0 (en) 1997-04-22 1997-06-11 Woolcombers Group Plc Compositions and their use
TW368420B (en) 1997-11-04 1999-09-01 Genetronics Inc Apparatus and method for transdermal molecular delivery by applying sufficient amplitude of electric field to induce migration of molecules through pores in the stratum corneum
AU1800099A (en) 1997-11-25 1999-06-15 Theratech, Inc. Transdermal delivery devices containing polydiorganosiloxane polymers to regulate adhesive properties
US6575956B1 (en) 1997-12-31 2003-06-10 Pharmasonics, Inc. Methods and apparatus for uniform transcutaneous therapeutic ultrasound
EP1045714A1 (fr) 1998-01-08 2000-10-25 Sontra Medical, L.P. Transport transdermique par sonophorese ameliore
CA2265119C (fr) 1998-03-13 2002-12-03 Cygnus, Inc. Biocapteur et systeme d'echantillonnage iontophoresique et methodes d'utilisation de ceux-ci
US7004933B2 (en) 1998-05-29 2006-02-28 Light Bioscience L.L.C. Ultrasound enhancement of percutaneous drug absorption
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
SE9802864D0 (sv) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
DE19850517B4 (de) 1998-11-03 2004-02-12 Lts Lohmann Therapie-Systeme Ag Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall
FR2785544B1 (fr) 1998-11-09 2001-01-05 Lhd Lab Hygiene Dietetique Electrode de transfert d'un courant electrique traversant la peau d'un patient
US5983135A (en) 1998-12-24 1999-11-09 Avrahami; Zohar Transdermal delivery of fine powders
DK1146908T3 (da) 1999-01-27 2005-10-10 Becker David Dr Formuleringer omfattende antisense-nukleotider mod connexiner
DK1189660T3 (da) 1999-06-08 2006-08-21 Altea Therapeutics Corp Apparat til mikroperforering af biologiske membraner ved hjælp af tyndfilms-vævsgrænseflade-anordninger samt fremgangsmåde til fremstilling deraf
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6512950B2 (en) 2000-02-18 2003-01-28 University Of Utah Research Foundation Methods for delivering agents using alternating current
US6706032B2 (en) 2000-06-08 2004-03-16 Massachusetts Institute Of Technology Localized molecular and ionic transport to and from tissues
US6487447B1 (en) 2000-10-17 2002-11-26 Ultra-Sonic Technologies, L.L.C. Method and apparatus for in-vivo transdermal and/or intradermal delivery of drugs by sonoporation
US6553255B1 (en) 2000-10-27 2003-04-22 Aciont Inc. Use of background electrolytes to minimize flux variability during iontophoresis
US6712805B2 (en) 2001-01-29 2004-03-30 Ultra Sonic Tech Llc Method and apparatus for intradermal incorporation of microparticles containing encapsulated drugs using low frequency ultrasound
US6893655B2 (en) 2001-10-09 2005-05-17 3M Innovative Properties Co. Transdermal delivery devices
US6750291B2 (en) 2002-04-12 2004-06-15 Pacific Corporation Film-forming agent for drug delivery and preparation for percutaneous administration containing the same
US7052715B2 (en) 2003-04-11 2006-05-30 All Natural Fmg, Inc. Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
US7033998B2 (en) 2003-04-11 2006-04-25 All Natural Fmg, Inc. Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
US7291591B2 (en) 2003-04-11 2007-11-06 All Natural Fmg, Inc. Alcohol-free transdermal insulin composition
US6951658B1 (en) 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
WO2007109347A2 (fr) * 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadhérine et ly6 e: cibles pour diagnostic et traitement du cancer
EP2091557A2 (fr) 2006-11-15 2009-08-26 Coda Therapeutics, INC. Méthodes et compositions améliorées pour la cicatrisation des plaies
CN101835476B (zh) * 2006-12-11 2016-08-17 科达治疗公司 作为受损伤口愈合组合物的抗连接蛋白多核苷酸
US20110144182A1 (en) 2007-12-21 2011-06-16 David Lawrence Becker Treatment of surgical adhesions
CA2710375A1 (fr) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Traitement des conditions orthopediques
AU2008343758A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
US20110038920A1 (en) * 2008-01-07 2011-02-17 Ryoichi Mori Wound healing compositions and treatments

Also Published As

Publication number Publication date
EP2831233A1 (fr) 2015-02-04
JP2015513905A (ja) 2015-05-18
CN104736709A (zh) 2015-06-24
WO2013148736A1 (fr) 2013-10-03

Similar Documents

Publication Publication Date Title
AU2018200326B2 (en) Improved methods and compositions for wound healing
US20110038920A1 (en) Wound healing compositions and treatments
US20100279921A1 (en) Impaired wound healing compositions and treatments
JP2015057430A (ja) 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
CA2868534A1 (fr) Compositions et traitements bases sur la modulation de la cadherine
US20170056468A1 (en) Treatment of resistant lesions
US20160244759A1 (en) Compositions and treatments based on cadherin modulation
CA2940648A1 (fr) Traitement des lesions resistantes
CA2941140A1 (fr) Traitement de lesions resistantes

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190326